Received Feb 24, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEPA | HEP A (HAVRIX) | GLAXOSMITHKLINE BIOLOGICALS | 3 | 95DB2 | — |
received a 3rd dose of HAVRIX (1440 EL.U./mL) in July 2024; This non-serious case was reported by a consumer via call center representative and described the occurrence of extra dose administered in a male patient who received HAV (Havrix 1440) (batch number 95DB2, expiry date 13-DEC-2024) for prophylaxis. Previously administered products included Havrix (received 1st dose of Havrix in 1998) and Havrix (received 2nd dose of Havrix in 1998). In JUL-2024, the patient received the 3rd dose of Havrix 1440. In JUL-2024, an unknown time after receiving Havrix 1440, the patient experienced extra dose administered (Verbatim: received a 3rd dose of HAVRIX (1440 EL.U./mL) in July 2024). The outcome of the extra dose administered was unknown. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 20-FEB-2025 The reporter reported that patient received 2 doses of Havrix 1440 vaccine in 1998 for prevention. The patient was going somewhere and eat a lot of seafood, and it was advised to get immunized. The patient received a 3rd dose of Havrix 1440 in July 2024, which led to extra dose administered. The manufacturer did not know how long the vaccines lasts. The patient did not have details of the Havrix from the 1998 immunization.